Physician profile
Wayne A Evron
NPI 1346268299
$7,054.06
in general payments reported to CMS, 2019-2025
33 companies · $1,304 in 2025
The $1,304 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,447 · 2020: $359 · 2021: $345 · 2022: $177 · 2023: $285 · 2024: $1,137 · 2025: $1,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,726.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $1,950.97 | 2019-2020 | |
| Lilly USA, LLC | $891.14 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $712.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $711.40 | 2019-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $478.69 | 2019-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $469.33 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $292.45 | 2019-2025 | |
| Medtronic, INC. | $275.34 | 2021-2025 | Inpen Smart Insulin Delivery System, Minimed 780g |
| Becton, Dickinson and Company | $173.53 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $147.61 | 2019-2020 | |
| Corcept Therapeutics | $144.88 | 2019-2025 | Korlym |
| Valeritas, INC. | $107.04 | 2019 | |
| Insulet Corporation | $100.37 | 2019-2024 | Omnipod |
| Amgen INC. | $65.80 | 2019-2024 | Repatha |
| Sequel Med Tech, LLC | $57.54 | 2025 | Twiist |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $53.28 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $51.80 | 2021 | |
| Madrigal Pharmaceuticals | $44.83 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $40.76 | 2019-2020 | |
| Acella Pharmaceuticals, LLC | $36.84 | 2025 | NP Thyroid 60 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.50 | 2019 | |
| Cequr Corporation | $32.75 | 2022-2023 | Cequr Simplicity |
| Regeneron Healthcare Solutions, INC. | $29.09 | 2019 | |
| Alvogen INC | $22.69 | 2025 | Teriparatide |
| Ipsen Biopharmaceuticals, INC | $20.31 | 2019 | |
| Antares Pharma, INC. | $19.18 | 2019 | |
| Neurocrine Biosciences, INC. | $16.49 | 2025 | |
| Amarin Pharma, INC. | $13.72 | 2020 | |
| Ibsa Pharma INC. | $13.21 | 2019 | |
| Xeris Pharmaceuticals, INC. | $12.33 | 2022 | |
| Lifescan, INC. | $11.39 | 2019 | |
| Aytu Biopharma, INC. | $10.80 | 2019 | |
| Beta Bionics, INC. | $10.41 | 2023 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Evron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.